PreveCeutical Medical Inc. (CSE: PREV) issued 8,600,000 units at $0.025 each for $215,000 in the fourth and final disclosed tranche of a non-brokered private placement, bringing total gross proceeds from the financing to $1,000,000.
The earlier closings were 13,600,000 units for $340,000 on May 12, 2026, 9,800,000 units for $245,000 on June 12, and 8,000,000 units for $200,000 on July 27. Together with the latest tranche, the offering has placed 40 million shares and 20 million warrants at a quarter of a Canadian cent above two cents per unit.
Each unit consists of one common share and half a warrant. A full warrant buys one additional share at $0.05 for two years from the closing of the fourth tranche — double the unit price, meaning the warrants only carry value if the stock roughly doubles from the placement level.
The warrants can be forced out early. If the daily closing price on the Canadian Securities Exchange reaches or exceeds $0.08 for ten consecutive trading days, PreveCeutical may accelerate expiry by news release, after which unexercised warrants lapse 30 days later.
The company also corrected an error in its four previous releases about the offering: the acceleration threshold had been stated as $0.10. According to the release, the correct figure is $0.08 for all tranches.
Fees and use of proceeds
PreveCeutical paid one eligible finder $17,200 in cash and issued 688,000 finder's warrants for the fourth tranche. Those warrants carry the same $0.05 exercise price, two-year term and acceleration provision. The cash fee equals 8 percent of the tranche's gross proceeds.
The company says the money from the fourth tranche is intended for short loan repayments, audit, accounting and legal fees, patent costs, further studies and analysis of rodents and tissues, and general working capital. That list places debt repayment and professional fees ahead of research spending, and the release does not break down how much goes to each item.
PreveCeutical did not disclose its cash position, monthly spending rate or total shares outstanding, so the dilution from the 40 million new shares cannot be measured from the release alone.
Securities issued in the fourth tranche are subject to a four-month-and-one-day hold period under Canadian securities law, after which they become freely tradeable.
The company describes itself as a health sciences business with five research and development programs, including gene therapy work aimed at diabetes and obesity, peptide analgesics and a concussion treatment candidate. None of those programs has been reported as generating revenue.
Source: Newsfile
This article is journalism, not investment advice. It is not an offer or solicitation to buy or sell any security. Micro-cap and penny stocks carry a high risk of loss, including illiquidity and dilution. Do your own research.